Esra Cansever Mutlu

Dr. Esra Cansever Mutlu

Metallurgy and Materials, University of Birmingham, Birmingham, UK
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Carbohydrate Polymers
Verified
Journal Article
Closed access
MBMuge Sennaroglu Bostan
Muge Sennaroglu Bostan
Esra Cansever MutluEsra Cansever Mutlu
Esra Cansever Mutlu
HKHande Kazak
Hande Kazak
SKS. Sinan Keskin
S. Sinan Keskin
EOEbru Toksoy Oner
Ebru Toksoy Oner
MEMehmet S. Eroglu
Mehmet S. Eroglu

26 April 2011 in Biomacromolecules
Verified
Journal Article
Closed access
Felix SimaFelix Sima
Felix Sima
Esra Cansever MutluEsra Cansever Mutlu
Esra Cansever Mutlu
MEMehmet S. Eroglu
Mehmet S. Eroglu
LSLivia Elena Sima
Livia Elena Sima
NSNatalia Serban
Natalia Serban
IMIon N. Mihailescu
Ion N. Mihailescu

Verified
Journal Article
Open access
PDF file
BURCAK YAVUZBURCAK YAVUZ
BURCAK YAVUZ
Esra Cansever MutluEsra Cansever Mutlu
Esra Cansever Mutlu
Zubair AhmedZubair Ahmed
Zubair Ahmed
BBBesim Ben-Nissan
Besim Ben-Nissan
Artemis StamboulisArtemis Stamboulis
Artemis Stamboulis
Extracellular vesicles (EVs), including exosomes, microvesicles, and other lipid vesicles derived from cells, play a pivotal role in intercellular communication by transferring information between cells. EVs secreted by progenitor and stem cells have been associated with the therapeutic effects observed in cell-based therapies, and they also contribute to tissue regeneration following injury, such as in orthopaedic surgery cases. This review explores the involvement of EVs in nerve regeneration, their potential as drug carriers, and their significance in stem cell research and cell-free therapies. It underscores the importance of bioengineers comprehending and manipulating EV activity to optimize the efficacy of tissue engineering and regenerative therapies.

4 April 2017 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
MEMehmet S. Eroglu
Mehmet S. Eroglu
EOEbru Toksoy Oner
Ebru Toksoy Oner
Esra Cansever MutluEsra Cansever Mutlu
Esra Cansever Mutlu
MBMuge Sennaroglu Bostan
Muge Sennaroglu Bostan
Since last decade, sugar based biopolymers are recognized in nanomedicine as promising materials for cancer imaging and therapy. Their durable, biocompatible and adhesive properties enable the fine tuning of their molecular weights (MW) and their miscellaneous nature makes the molecules acquire various conformations. These in turn provide effective endocytosis by cancer cell membranes that have already been programmed for internalization of different kinds of sugars. Therefore, biocompatible sugar based nanoparticles (SBNPs) are suitable for both cell-selective delivery of drugs and imaging through the human body. Recently, well known sugar-based markers have displayed superior performance to overcome tumor metastasis. Thereby, targeting strategies for cancer cells have been broadened to sugar-based markers as noticed in various clinic phases. In these studies, biopolymers such as chitosan, hyaluronic acid, mannan, dextran, levan, pectin, cyclodextrin, chondroitin sulphate, alginates, amylose and heparin are chemically functionalized and structurally designed as new biocompatible nanoparticles (NPs). The future cancer treatment strategies will mainly comprise of these multifunctional sugar based nanoparticles which combine the therapeutic agents with imaging technologies with the aim of rapid monitoring response to therapies. While each individual imaging and treatment step requires a long time period in effective treatment of diseases, these multifunctional sugar based nanoparticles will have the advantage of rapid detection, right drug efficiency evaluation and immediate interfere opportunity to some important diseases, especially rapidly progressing cancers. In this article, we evaluated synthesis, characterization and applications of main sugar based biopolymers and discussed their great promise in nano-formulations for cancer imaging and therapy. However much should be done and optimized prior to clinical applications of these nano-formulations for an efficient drug treatment without overall toxicity for getting most effective clinical results.

14 March 2018 in Hacettepe Journal of Biology and Chemistry
Verified
Journal Article
Closed access
AYArzu Birinci Yıldırım
Arzu Birinci Yıldırım
Esra Cansever MutluEsra Cansever Mutlu
Esra Cansever Mutlu
MYMuhammet Yıldırım
Muhammet Yıldırım

27 July 2020 in Materials
Verified
Journal Article
Open access
PDF file
Esra Cansever MutluEsra Cansever Mutlu
Esra Cansever Mutlu
ÖKÖzge Kaya
Özge Kaya
MWMatthew Wood
Matthew Wood
IMImre Mager
Imre Mager
KÇKübra Çelik
Kübra Çelik
JBJale Odabaşı Bağcı
Jale Odabaşı Bağcı
Immature dendritic cells (IDc), ‘dexosomes’, are promising natural nanomaterials for cancer diagnose and therapy. Dexosomes were isolated purely from small-scale-up production by using t25-cell-culture flasks. Total RNA was measured as 1.43 ± 0.33 ng/106 cell. Despite the fact that they possessed a surface that is highly abundant in protein, this did not become a significant effect on the DOX loading amount. Ultrasonication was used for doxorubicin (DOX) loading into the IDc dexosomes. In accordance with the literature, three candidate DOX formulations were designed as IC50 values; dExoIII, 1.8 µg/mL, dExoII, 1.2 µg/mL, and dExoI, 0.6 µg/mL, respectively. Formulations were evaluated by MTT test against highly metastatic A549 (CCL-185; ATTC) cell line. Confocal images of unloaded (naïve) were obtained by CellMaskTM membrane staining before DOX loading. Although, dexosome membranes were highly durable subsequent to ultrasonication, it was observed that dexosomes could not be stable above 70 °C during the SEM-image analyses. dExoIII displayed sustained release profile. It was found that dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) results were in good agreement with each other. Zeta potentials of loaded dexosomes have approximately between −15 to −20 mV; and, their sizes are 150 nm even after ultrasonication. IDcJAWSII dexosomes can be able to be utilized as the “BioNanoMaterial” after DOX loading via ultrasonication technique.